Home/Filings/4/0001209191-23-002664
4//SEC Filing

Elting Kimberley A. 4

Accession 0001209191-23-002664

CIK 0000884624other

Filed

Jan 8, 7:00 PM ET

Accepted

Jan 9, 7:12 PM ET

Size

13.6 KB

Accession

0001209191-23-002664

Insider Transaction Report

Form 4
Period: 2023-01-05
Elting Kimberley A.
Chief Legal Officer
Transactions
  • Award

    Common Stock

    2023-01-05+35,129140,924 total
  • Award

    Common Stock

    2023-01-05+12,229164,687 total
  • Award

    Employee Stock Option (Right to Buy)

    2023-01-05+84,56684,566 total
    Exercise: $20.90Exp: 2033-01-05Common Stock (84,566 underlying)
  • Award

    Common Stock

    2023-01-05+11,534152,458 total
  • Award

    Common Stock

    2023-01-05+20,492185,179 total
Footnotes (5)
  • [F1]The restricted stock units vest with respect to one-third (1/3rd) of the shares of stock covered hereby on each of the first, second and third anniversaries of the Grant Date.
  • [F2]Represents outstanding performance stock units for awards granted in 2020, which as a result of the Orthofix Board's determination to treat the merger with SeaSpine Holdings Corporation as a change in control (referred to as a "corporate transaction" under Orthofix's Amended and Restated 2012 Long-Term Incentive Plan) were deemed achieved at target levels as of the merger date and converted to time-based awards that vest on June 8, 2023.
  • [F3]Represents outstanding performance stock units for awards granted in 2021, which as a result of the Orthofix Board's determination to treat the merger with SeaSpine Holdings Corporation as a change in control (referred to as a "corporate transaction" under Orthofix's Amended and Restated 2012 Long-Term Incentive Plan) were deemed achieved at target levels as of the merger date and converted to time-based awards that vest on April 1, 2024.
  • [F4]Represents outstanding performance stock units for awards granted in 2022, which as a result of the Orthofix Board's determination to treat the merger with SeaSpine Holdings Corporation as a change in control (referred to as a "corporate transaction" under Orthofix's Amended and Restated 2012 Long-Term Incentive Plan) were deemed achieved at target levels as of the merger date and converted to time-based awards that vest on January 31, 2025.
  • [F5]The options vest and become exercisable with respect to one-third (1/3rd) of the shares covered thereby on the first anniversary of the Grant Date and one-twelfth (1/12th) of the shares covered thereby on each of the 15-month, 18-month, 21-month, 24-month, 27-month, 30-month, 33-month and 36-month anniversaries of the Grant Date.

Issuer

Orthofix Medical Inc.

CIK 0000884624

Entity typeother

Related Parties

1
  • filerCIK 0001605209

Filing Metadata

Form type
4
Filed
Jan 8, 7:00 PM ET
Accepted
Jan 9, 7:12 PM ET
Size
13.6 KB